The healthtech startup Dermagnostix aims to close the gap between highly effective therapeutics and outdated diagnostic procedures in dermatology. A molecular diagnostic point-of-care device is used to differentiate psoriasis from eczema. The young company will be represented at the conference by Katharina Dormanns, CTO and co-founder. (Photo: Science4Life)